Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma

por DeConti, R C, Algazi, A P, Andrews, S, Urbas, P, Born, O, Stoeckigt, D, Floren, L, Hwang, J, Weber, J, Sondak, V K, Daud, A I
Publicado 2010

Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma

por Daud, A. I., Xu, C., Hwu, W.-J., Urbas, P., Andrews, S., Papadopoulos, N. E., Floren, L. C., Yver, A., DeConti, R. C., Sondak, V. K.
Publicado 2010

Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma

por Algazi, A P, Weber, J S, Andrews, S C, Urbas, P, Munster, P N, DeConti, R C, Hwang, J, Sondak, V K, Messina, J L, McCalmont, T, Daud, A I
Publicado 2012

The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II...

por Algazi, A P, Cha, E, Ortiz-Urda, S M, McCalmont, T, Bastian, B C, Hwang, J, Pampaloni, M H, Behr, S, Chong, K, Cortez, B, Quiroz, A, Coakley, F, Liu, S, Daud, A I
Publicado 2015